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ABSTRACT 
Cancer is one of the leading causes of death in the world. Solid tumors account for 90% of all cancers. Despite rapid developments in the conventional 
modalities of cancer treatment (chemotherapy and radiotherapy) there is still no definitive “cure” for cancer. The present observation aims to an eye on 
alternative cancer therapies.  The search for alternative therapies dates back to early 1800’s when a patient was observed to recover spontaneously following 
an infection. This resulted in the birth of Coley’s toxin for the treatment of sarcomas and use of live Bacillus Calmette – Guerin (BCG) for bladder cancer. The 
same provoked for a series of researches in this field, but was heralded due to lack of specificity, lack of complete tumor lyses and ineffectiveness against 
small tumors. However with the advent of recombinant DNA technology and its developments, it has paved the way for a new era for a tumor- targeted 
bacterial vector system for gene therapy of solid tumors. In this review we will discuss the potential of genetically manipulated bacteria that will usher in the 
new era of bacterial therapy for solid tumors. 
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INTRODUCTION 
Cancer is distinguished by uncontrolled and invasive growth 
of cells. These groups of cells may spread to other parts of 
the  body  and  is  called  as  ‘Metastasis’.  Cancer  has  been 
considered  as  one  of  the  lethal  diseases  from  antediluvian 
time itself. Even though various researches and studies about 
cancer therapeutics are going on, no proper cure for cancer 
has been invented so far. Although conventional therapeutic 
methods  for  cancer  consisting  of  radiotherapy  and 
chemotherapy  exist,  for  about  half  of  the  cancer  victims, 
these are ineffective
1.As a result of the low successive rates 
in  conventional  cancer  therapies,  advanced  researches  and 
studies led to experimental cancer treatments. Experimental 
cancer treatment can be briefed as medical therapies used to 
treat  cancer  by  remodeling,  reinforcing  or  substituting 
prevailing methods. Experimental cancer treatments include 
Photodynamic therapy, HAMLET, Telomerase therapy, Gene 
therapy,  Hyperthermia  therapy,  Dichloroacetate  (DCA), 
Insulin  potentiating  therapy,  Diet  therapy,  Complementary 
and Alternative therapy, Non-invasive RF  cancer treatment 
and  Bacterial  treatment
2.  But  many  of  these  therapies  are 
uncertain  due  to  lack  of  evidence,  availability,  specificity, 
selectivity and other related factors. With the help of certain 
advanced research methodologies, it’s been found that certain 
microorganisms could be used for controlling the growth of 
cancerous  cells  over  the  affected  areas.  Many  viruses  like 
vaccinia  virus,  reovirus,  Newcastle  disease  virus  and 
adenovirus  with  an  E1a  deletion,  which  are  engaged  to 
achieve  selective  replica  and  destruction  of  tumour  cells, 
werestudied  in  detail
3.  Viruses  are  referred  as  the  most 
commonly  used  micro-organisms  to  carry  altered  genes  to 
cancer  cells,  and  they  latches  on  to  the  cancerous  cells. 
Oncolytic  viruses  cause  rupture  of  cancer  cells  but  the 
effective use of such viruses is sometimes prohibited by the 
production of potentially overriding antibodies generated in 
contrast to them. It was then came the vital role of bacteria in 
cancer  therapeutic  methods
4.  Studies  and  researches  have 
stated  that  certain  bacterial  species  can  be  used  as  cancer 
therapeutic agents as active elements. Moreover they possess 
certain advantageous features over viruses such as motility, 
capacity  to  simultaneously  carry  therapeutic  proteins  and 
nutrients and resistivity against antibiotics. These all features 
concluded bacterial treatment as a promising tactical method 
in cancer treatment. 
 
Background 
The  role  of  bacteria  as  an  anticancer  agent  was 
recognizedalmost  hundred  years  back.  Even  though  the 
invention  was  accidental,  it  led  to  many  successful 
developments in cancer therapeutics. The German physicians 
W.  Busch  and  F.  Fehleisen  separately  noticed  that  certain 
types  of  cancers  reverted  following  accidental  erysipelas 
infections that occurred while the patients were hospitalized. 
Independently,  an  American  physician  William  Coley 
observed that one of his patients suffering from neck cancer 
began  to  recover  following  an  infection  with  erysipelas. 
Later, he started researching about the disease, erysipelas. As 
a  result  of  his  experimental  strategies,  he  recognized  the 
pathogen  of  erysipelas  as  Streptococcus  pyogenes
5.His 
inventions led the milestone of cancer therapy methods with 
the  help  of  bacteria  and  began  well  documented  use  of 
bacteria and their toxins to treat solid tumours.  He developed 
a  vaccine  in  the  late  1800’s  with  the  help  of  two  killed 
bacterial  species  Streptococcus  pyogenes  and  Serratia 
marcescens
6  and  this  vaccine  was  widely  used  to  treat 
patients  who  were  suffering  from  sarcomas,  carcinomas, 
lymphomas  and  related  diseases.  The  treatment  responded 
with prolonged regression  of advanced  malignant stages in 
most  of  the  cases.  ‘Coley’s  toxin’  was  also  studied  for 
potential  anticancer  therapy
7.  The  prevenient  success  of 
Coley’s Toxin accounted for current and further researches in 
this area. 
   
Bacterial Therapy 
After  Coley  had  developed  the  toxin  (1800’s),  advanced 
researches in bacterial therapy for cancer was introduced by a 
group  of  scientists.  They  identified  certain  species  of 
anaerobic  bacteria;  those  belonging  to  Clostridium  genus Preenu P Sen et al. Int. Res. J. Pharm. 2013, 4 (5) 
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were the ones responsible for the actual cause of the positive 
response  shown  by  Coley’s  toxin
8.  These  findings  made 
bacteria  as  one  of  the  primary  Oncolytic  agents.  Since, 
bacteria alone were not able to cure all parts of the malignant 
tissues,  by  combining  radiotherapy  and  chemotherapy  with 
bacterial  therapy,  a  new  methodology  was  invented  for 
cancer therapy.  Thus bacteria can  be significant supporting 
element  for  current  anticancer  therapies  which  include 
chemotherapy and radiotherapy
9. 
Bacterial products like endotoxins have already shown better 
results  in  anticancer  therapy.  These  cancer  vaccines  are 
mainly based on immunotoxins of bacterial origin. Bacteria 
can be used as delivery agents for anticancer drugs and as 
vectors for gene therapy. 
Our body is comprised of numerous cells which undergoes 
cell division. All these activities are controlled by molecules 
in our body. Normal cells regenerate in a proper manner and 
they will be shattered after the proposed cell life. But, in a 
cancerous  site,  the  cells  regenerate  again  and  again 
inconsistently  and  pass  through  uncontrolled  multiple  cell 
divisions.  This  abnormal  activity  leads  to  the  formation  of 
cancer  lumps  and  masses  at  different  part/s  of  the  body, 
which in turn leads to solid tumors. Cancerous cells multiply 
continuously contrary to normal cell growth.  
Nutrients are one of the essential elements required for the 
body. Our body has its own mechanism in procurement of 
nutrients. Normally, blood vessels act as carriers of nutrients 
all over the  body.  In  a cancerous state, nutrients won’t  be 
reaching  the  cancer  affected  areas  properly.  In  this  state, 
alternative  blood  vessels  will  be  formed  by  the  cells  for 
meeting  the  adequate  nutrient  requirements.  Even  though 
alternative blood vessels exist, they won’t be able to meet the 
normal functionality of a blood vessel. Moreover enormous 
cancer  masses  will  be  present  here.  These  areas  will  be 
oxygen  deficient  and  are  commonly  termed  as  Oxygen 
deprived areas
10. 
Since the cancerous area consist anaerobic portions too, the 
ideology of using anaerobic bacteria for the treatment of solid 
tumors  paved  a  new  lead  against  solid  tumors.  Several 
scientists  and  genetically  expertise  people  discussed  about 
this  and  concluded  anaerobic  bacteria  as  a  promising 
assisting agent for solid tumors or cancers. The process what 
they explained was about inflowing anaerobic bacteria to the 
anaerobic  portions  of  the  cancerous  area.  Since  anaerobic 
bacteria becomes active in oxygen deprived environment, the 
anaerobic sites of cancerous area was considered as perfect 
sites for  breeding of these species.  These bacteria  multiply 
and  destroy  the  cancerous  cells  present  in  the  anaerobic 
portions present in the solid tumors. This was considered as 
an  efficient  treatment  procedure  against  cancer  until  the 
problem of infections caused by bacteria aroused
11. Bacteria 
cannot  be  directly  inoculated  inside  the  body.  Several  risk 
factors like occurrence of bacterial infections, disturbing the 
immune system of the body etc. aroused. As a result of all 
these  problems,  bacterial  treatment  procedures  in  cancer 
therapy were immobilized, since these problems could not be 
stabilized  at  ancient  times.  Later,  the  knowledge  about 
Polymerized Chain Reaction, Recombinant DNA Technology 
and  Genetic  Engineering  paved  the  way  for  further 
developments  in  the  treatment  of  cancer  with  the  help  of 
anaerobic bacteria
12. 
 
Bacteria as Anticancer Agents 
Since after the progressions in Genetical Engineering, several 
techniques  were  proposed  for  hosting  anaerobic  bacteria 
inside  the  body  for  treatment  of  solid  tumors  and  cancers. 
Among them the  most  prevailed was the use of attenuated 
bacteria  for  cancer  therapy.  The  use  of  live,  attenuated  / 
weakened or genetically modified bacteria begun to emerge 
as potential anticancer agents.  Spores of anaerobic bacteria 
are used in cancer therapeutic methods. It’s mainly because 
only  spores  that  reach  the  oxygen  deprived  area  could 
germinate,  multiply  and  become  lively  and  thereby 
energizing the activity
13. The primary bacteria experimented 
for the cancer therapy was bacteria belonging to clostridium 
class. Even though it showed better results the animals which 
were  experimented  on  died  due  to  acute  toxicity.  This 
resulted  to  the  focus  of  a  non-pathogenic  strand  of 
Clostridium such as M55, which showed promising results. 
The species were able to colonize the anaerobic areas of the 
cancerous tissues and succeeded in preventing the activity of 
proposed  cancerous  site  but  were  not  able  to  produce 
substantial  tumor  regression.  Recently,  a  lot  of  bacterial 
species have been checked for their ability against cancers, 
but most of them concluded in death. C. novyi – NT was one 
among them obtained after removing a gene arrangement for 
a lethal toxin showed promising results but produced toxicity 
which made them inappropriate for cancer therapy
14. 
 
 
 
Figure 1: hypoxia targeting therapy with bacterial spores 
(Source: http://www.chordomafoundation.org/latest-updates/clinical-trial-
using-novel-cancer-killing-bacteria-opens-to-chordoma-patients/ [Date of 
Browsing: 14-05-2013]) 
 
Since C. Novyi- NT spores  showed promising results with 
toxin generation as a major defect, a series of researches were 
carried out about using the same  vector  for cancer therapy 
along  with  conventional  methods  like  chemotherapy  and 
radiotherapy.  This  strategy  was  known  as  Combination 
Bacteriolytic  Therapy  (COBALT)
  15.  It  showed  significant 
anti-  a  cancer  therapy  but  still  wasn’t  able  to  provide 
completely successive results. Later, lipomase was identified 
as  the  factor  responsible  for  enhanced  drug  release  in 
bacteria.  In-  vivo  experiments  were  carried  out  in  many 
species  of  animals  for  screening  the  efficiency  of  the 
bacterium.  C.  novyi-  NT  along  with  a  single  dose  of 
liposomal  doxorcubicin  led  to  further  studies  in  this  area. 
Later, Recombinant DNA Technology was introduced and C. 
novyi- NT undergone this method by combining with anti- 
microtubule  agents.  The  results  showed  that  microtubule 
destabilizers  such  as  vinorelbine  and  HTI-  286  helped  in 
reducing the blood flow to cancerous sites and thereby helped 
in forming a hypoxic area for spore germination for anaerobic 
bacteria.  The  most  successfully  tested  bacteria  so  far  are Preenu P Sen et al. Int. Res. J. Pharm. 2013, 4 (5) 
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Bacillus Calmette- Geurin (BCG). It is generally used for the 
treatment of superficial bladder cancer
16. 
Salmonella typhimurium is another species which has been 
developed  for  cancer  treatment.  Deletion  of  its  two  genes 
from the normal DNA strand resulted in complete attenuated 
form  of  the  species  making  it  suitable  for  cancer  therapy. 
This vector showed prolonged efficiency against wide range 
of  tumors  and  cancers,  and  was  able  to  destroy  metastatic 
lesions.  The  major  advantage  of  using  Salmonella 
typhimurium instead  of  clostridium  species is its ability to 
germinate  in  both  aerobic  and  anaerobic  environment, 
indicating its activity against normal tumors too. VNP20009 
is  another  vector  which  has  been  successfully  tested  in 
clinical trials in cancer patients.  It is sure that  other alive, 
attenuated  forms  of  bacteria  like  Bifidobacterium  will  be 
assessed in human medical trials in future. Some of the new 
strains  of  bacteria  species  which  are  being  investigated  as 
anti-  cancer  agents  are:  Vibrio  cholera,  Listeria 
monocytogenes, Salmonella choleraesuis, E. coli and certain 
bacteria from Clostridium species
17. 
 
Bacteria and Gene Therapy 
Bacterial  approaches  in  the  treatment  of  cancer  showed 
promising results with minor faults. The major problem with 
using bacterial species as anti- cancer agents is their amount 
of toxicity generated. Researchers were not sure whether the 
toxicity produced by the vectors were much enough for the 
therapeutic  efficiency.  Another  obstacle  faced  was  the 
targeting of specific area to a solid tumor. As a solution for 
this,  gene  therapy  was  encompassed  with  the  existing 
anaerobic  bacterial species. Genetically engineered  bacteria 
were used as a result of this technology to prompt a precise 
therapeutic gene. Proteins of desired interests were developed 
in the cancerous  environment; these  bacteria  acted as drug 
enhancing  agents  to  various  cancer  therapies.  Thus 
genetically modified bacteria were developed and they serve 
as  active  vectors  for  delivering  anticancer  cancer  agents, 
therapeutic proteins and cytotoxic peptides
18. 
 
Enzyme Prodrug Therapy 
This strategy is used to overcome the side effects caused by 
the bacterial therapy and uses the hypoxic bacterial species 
that have been genetically modified with a desired enzyme 
which  converts  a  non-  toxic  prodrug  into  a  toxic  drug  for 
bacterial cancer therapy.  Thus a  scientifically derived drug 
was  used  in  cancer  therapy.  Nowadays,  several  enzyme 
producing prodrug are available. The salmonella species were 
also tested successfully. High levels of activity are detected 
in  tumors  after  in  vivo  administration  motivating  further 
research. Both the prodrug and activated drug must be able to 
cross  biological  membranes  for  significant,  because  the 
prodrug  will  be  stimulated  within  bacterial  cells  and  the 
active  drug  will  then  need  to  enter  the  cancerous  cells. 
Reformed B. longum  by  pBLES100-S-eCD  yields cytosine 
deaminase  in  the  anaerobic  tumor,  and  studies  have 
concluded this as an effective prodrug-enzyme therapy
19. 
 
Bacterial Spores 
The majority of the anaerobic bacteria can form exceedingly 
resistant spores which allow them to survive even in aerobic 
environment,  even  though  they  cannot  germinate  and 
multiple there. But once they meet the anaerobic conditions, 
the  species  become  active  and  germination  process  will 
flourish making them ideal to target cancers. C. novyi- NT 
has  shown  promising  results  without  any  side  effects. 
Pharmacologic and toxicological evaluation of these species 
found that the spores were rapidly wiped from the circulation 
by the normal reticuloendothelial system. Bacterial spores are 
considered  as  one  of  the  best  delivery  agents  for  cancer 
therapeutics.  A  summary  of  significant  clinical  trials  using 
bacteria are shown in the table
20. 
 
Table 1: List of genetically modified bacteria and their research phase 
 
Intervention  Clinical trial phase  Present status  Disease conditions  Reference 
VNP20009 (Attenuated 
Salmonella) 
Phase I  Completed  Metastatic solid tumors  Bacteria in Cancer Therapy: A 
Novel Experimental Strategy 
(S Patyar et al.,2009) 
TAPET-CD (Attenuated 
strain of Salmonella 
typhimurium) 
Phase I  Completed  Neck, head and esophagus cancer  Bacteria in Cancer Therapy: A 
Novel Experimental Strategy 
(S Patyar et al.,2009) 
Tf-107 CRM (Diphteria 
toxin) 
Phase I  Completed  Brain and Nervous system tumors  Bacteria in Cancer Therapy: A 
Novel Experimental Strategy 
(S Patyar et al.,2009) 
IL4-PE- Interleukin-4-
Pseudomonas exotoxin 
Phase I  In progress  Brain and Nervous system tumors  Bacteria in Cancer Therapy: A 
Novel Experimental Strategy 
(S Patyar et al.,2009) 
IL13-PE- Interleukin-13-
Pseudomonas exotoxin 
 
Phase I  In progress  Malignant Glioma, 
GlioblastomaMultiforme, Anaplastic 
Astrocytoma, Anaplastic 
Oligodendroglioma and Mixed 
Oligoastrocytoma 
Bacteria in Cancer Therapy: A 
Novel Experimental Strategy 
(S Patyar et al.,2009) 
Listeria Bacteria 
(Genetically modified 
Radioactive Bacteria) 
Phase I  Completed  Malignant Pancreatic Cancer  www.einstein.yu.edu 
(DOA: 14-05-2013) 
 
Problems Regarding Bacterial Therapy 
One  of  the  major  problems  with  using  bacteria  as  an 
anticancer agent was the release of toxic substances within 
the body which may rupture the immune system of the body. 
Systemic infections caused by bacteria were another concern. 
Another  main  problem  was  incomplete  tumor  lysis  i.e., 
bacteria won’t consume all areas of the solid tumor, mainly 
anaerobic  sites  are  considered  as  the  active  sites  for  spore 
germination and further procedures. In case of bacterial gene 
therapy, the major obstacle is the inaccessibility because most 
of the times an intratumoural injection is essential. Another 
major concern was about the potential for DNA mutations. 
Any  loss  in  functionality  due  to  mutations  can  result  into 
various problems. Although some of the above concerns have 
been solved with the recombinant DNA technology  further 
developments are yet to be made
21. Preenu P Sen et al. Int. Res. J. Pharm. 2013, 4 (5) 
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CONCLUSION 
The journal focuses on the revolutionary role of bacteria in 
cancer  therapy.  Various  trials  conducted  in  mouse  tumor 
models have proved beyond doubt the potency of bacteria in 
eradicating  this  deadly  disease.  However,  the  successful 
translation of these preclinical strategies into clinical practice 
will depend on the outcome  of ongoing clinical trials. The 
availability  of  recombinant  DNA  technology  and  other 
modern  modalities  which  includes  the  use  of  radioactive 
bacterial  species  along  with  conventional  cancer  therapy 
methods of chemotherapy and radiotherapy has  provided  a 
cutting edge for ongoing clinical trials. 
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